Literature DB >> 12359865

Genetic polymorphisms of the human MDR1 drug transporter.

Matthias Schwab1, Michel Eichelbaum, Martin F Fromm.   

Abstract

P-glycoprotein is an ATP-dependent efflux pump that contributes to the protection of the body from environmental toxins. It transports a huge variety of structurally diverse compounds. P-glycoprotein is involved in limiting absorption of xenobiotics from the gut lumen, in protection of sensitive tissues (brain, fetus, testis), and in biliary and urinary excretion of its substrates. P-glycoprotein can be inhibited or induced by xenobiotics, thereby contributing to variable drug disposition and drug interactions. Recently, several SNPs have been identified in the MDR1 gene, some of which can affect P-glycoprotein expression and function. Potential implications of MDR1 polymorphisms for drug disposition, drug effects, and disease risk are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359865     DOI: 10.1146/annurev.pharmtox.43.100901.140233

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  57 in total

Review 1.  Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

2.  Lack of association between MDR1 C3435T polymorphism and chemotherapy response in advanced breast cancer patients: evidence from current studies.

Authors:  Guodi Chen; Sheng Quan; Qiongge Hu; Liancong Wang; Xiaoping Xia; Jing Wu
Journal:  Mol Biol Rep       Date:  2011-12-09       Impact factor: 2.316

Review 3.  Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease.

Authors:  Jens Pahnke; Olaf Wolkenhauer; Markus Krohn; Lary C Walker
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

Review 4.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

5.  GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia.

Authors:  Martin Stanulla; Elke Schäffeler; Stefan Arens; Anke Rathmann; André Schrauder; Karl Welte; Michel Eichelbaum; Ulrich M Zanger; Martin Schrappe; Matthias Schwab
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

6.  Reduced ABCB1 Expression and Activity in the Presence of Acrylic Copolymers.

Authors:  Ramin Mohammadzadeh; Behzad Baradaran; Hadi Valizadeh; Bahman Yousefi; Parvin Zakeri-Milani
Journal:  Adv Pharm Bull       Date:  2014-02-07

7.  Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia.

Authors:  Hui He; Jiye Yin; Xi Li; Yu Zhang; Xiaojing Xu; Ming Zhai; Juan Chen; Chenyue Qian; Honghao Zhou; Zhaoqian Liu
Journal:  Eur J Clin Pharmacol       Date:  2015-01-09       Impact factor: 2.953

8.  Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.

Authors:  Kari T Kivistö; Jörg Zukunft; Ute Hofmann; Mikko Niemi; Sabine Rekersbrink; Swetlana Schneider; Gerd Luippold; Matthias Schwab; Michel Eichelbaum; Martin F Fromm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-30       Impact factor: 3.000

9.  Substrate-dependent effects of human ABCB1 coding polymorphisms.

Authors:  Jason M Gow; Laura M Hodges; Leslie W Chinn; Deanna L Kroetz
Journal:  J Pharmacol Exp Ther       Date:  2008-02-20       Impact factor: 4.030

10.  Role of multidrug transporters in neurotherapeutics.

Authors:  Manna Jose; Sanjeev V Thomas
Journal:  Ann Indian Acad Neurol       Date:  2009-04       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.